New Guidance Helps Clinicians Use Pemivibart to Protect Immunocompromised Patients From COVID-19.

Publication date: Sep 13, 2024

Open Access PDF

Concepts Keywords
Clinicians Clinicians
Covid Covid
Drugs Drugs
Immunocompromised Guidance
Helps
Immunocompromised
Jama
Pemivibart
Protect

Semantics

Type Source Name
disease MESH Immunocompromised Patients
disease MESH COVID-19
disease MESH leukemia
disease MESH lymphoma
disease IDO cell
drug DRUGBANK Nonoxynol-9
disease MESH infection
disease MESH complications
disease MESH death
disease MESH Infectious Diseases
disease MESH Emergency
drug DRUGBANK Indoleacetic acid
disease MESH Allergy
drug DRUGBANK Coenzyme M
pathway REACTOME Immune System
disease MESH anaphylaxis
disease IDO susceptibility
drug DRUGBANK Aspartame
disease IDO host

Original Article

(Visited 2 times, 1 visits today)